The Neuroprotective Agents Market was valued at USD 43.9 Billion in 2025, and is projected to reach USD 60.9 Billion by 2030, rising at a CAGR of 6.7%.
The neuroprotective agents market is gaining significant traction globally due to the rising incidence of neurological disorders and the growing understanding of neurodegenerative mechanisms. These agents, designed to preserve neuronal structure and function, are being explored across a broad range of therapeutic areas, including Alzheimer’s disease, Parkinson’s disease, stroke, traumatic brain injury and multiple sclerosis. Advances in neuroscience and molecular biology have accelerated the identification of new neuroprotective pathways and drug targets, fostering innovation in both small-molecule and biologic therapies. The shift from purely symptomatic treatments to disease-modifying strategies has further expanded research interest, with pharmaceutical and biotechnology companies intensifying efforts to develop compounds that can halt or reverse neuronal damage.
Globally, the market is experiencing robust momentum driven by the development of healthcare infrastructure, increased research funding and rising awareness of neurological health. Developed regions are leading in innovation and clinical trial activity, supported by strong regulatory frameworks and advanced healthcare systems. Meanwhile, emerging economies are showing rapid adoption potential due to improving diagnostic capabilities, expanding healthcare investments and a growing burden of neurological diseases linked to aging populations and lifestyle factors. As technological advancements in neuroimaging, drug delivery and precision medicine continue to evolve, the global neuroprotective agents’ market is poised to advance toward more effective, accessible and personalized therapeutic solutions.
This report focuses on different indications, such as neurodegenerative disorders, cerebrovascular disease, ophthalmic diseases and central nervous system (CNS) injuries. It segments neurodegenerative disorders into multiple sclerosis, Alzheimer’s disease, epilepsy, Parkinson's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and Huntington's disease. Ophthalmic diseases are segmented into age-related macular degeneration, glaucoma and other ophthalmic diseases. Based on drug class, the market is divided into immune response modifiers, blood thinning agents, anti-angiogenic agents, antioxidants, ocular hypotensives, anti-dementia agents, anticonvulsants, thrombolytics, anti-Parkinson's agents, antisense agents, anti-amyloid agents and other neuroprotective agents.
On the basis of therapy type, the overall market is segmented into small molecule drugs, monoclonal antibodies, cell therapies, gene therapies and other biotechnology products. The report also covers market projections throughout 2030 and company profiles. By geography, it is segmented into North America, Europe, Asia-Pacific, the MEA, and South America. North America includes the U.S., Canada, and Mexico; Europe includes Germany, the U.K., France, Italy, Spain, and the Rest of Europe; and Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. The study provides market estimates for 2024, with forecasts for 2025 through 2030.
The neuroprotective agents market is gaining significant traction globally due to the rising incidence of neurological disorders and the growing understanding of neurodegenerative mechanisms. These agents, designed to preserve neuronal structure and function, are being explored across a broad range of therapeutic areas, including Alzheimer’s disease, Parkinson’s disease, stroke, traumatic brain injury and multiple sclerosis. Advances in neuroscience and molecular biology have accelerated the identification of new neuroprotective pathways and drug targets, fostering innovation in both small-molecule and biologic therapies. The shift from purely symptomatic treatments to disease-modifying strategies has further expanded research interest, with pharmaceutical and biotechnology companies intensifying efforts to develop compounds that can halt or reverse neuronal damage.
Globally, the market is experiencing robust momentum driven by the development of healthcare infrastructure, increased research funding and rising awareness of neurological health. Developed regions are leading in innovation and clinical trial activity, supported by strong regulatory frameworks and advanced healthcare systems. Meanwhile, emerging economies are showing rapid adoption potential due to improving diagnostic capabilities, expanding healthcare investments and a growing burden of neurological diseases linked to aging populations and lifestyle factors. As technological advancements in neuroimaging, drug delivery and precision medicine continue to evolve, the global neuroprotective agents’ market is poised to advance toward more effective, accessible and personalized therapeutic solutions.
Report Scope
This report presents both qualitative and quantitative data on the current market dynamics and trends in the global neuroprotective agents market. It also assesses pipeline drugs that are under development. The study further includes analyses of various products offered by companies, new strategies implemented by major manufacturers and emerging technologies. It discusses the market prospects for five regions - North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) and includes profiles of leading companies and their strategies.This report focuses on different indications, such as neurodegenerative disorders, cerebrovascular disease, ophthalmic diseases and central nervous system (CNS) injuries. It segments neurodegenerative disorders into multiple sclerosis, Alzheimer’s disease, epilepsy, Parkinson's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and Huntington's disease. Ophthalmic diseases are segmented into age-related macular degeneration, glaucoma and other ophthalmic diseases. Based on drug class, the market is divided into immune response modifiers, blood thinning agents, anti-angiogenic agents, antioxidants, ocular hypotensives, anti-dementia agents, anticonvulsants, thrombolytics, anti-Parkinson's agents, antisense agents, anti-amyloid agents and other neuroprotective agents.
On the basis of therapy type, the overall market is segmented into small molecule drugs, monoclonal antibodies, cell therapies, gene therapies and other biotechnology products. The report also covers market projections throughout 2030 and company profiles. By geography, it is segmented into North America, Europe, Asia-Pacific, the MEA, and South America. North America includes the U.S., Canada, and Mexico; Europe includes Germany, the U.K., France, Italy, Spain, and the Rest of Europe; and Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. The study provides market estimates for 2024, with forecasts for 2025 through 2030.
The report includes:
- 54 data tables and 56 additional tables
- An overview of the global market for neuroprotective agents and their therapeutic applications
- In-depth analysis of global market trends, featuring historical revenue data for 2022-2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
- Evaluation of the current market size and revenue growth prospects specific to the neuroprotective agents, accompanied by a market share analysis by therapy type, indication, drug class, and region
- Analysis of current and future demand in the global neuroprotective agents market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
- Analysis of drivers, challenges and opportunities affecting market growth
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Market share analysis of the key market participants in the neuroprotective agents market, along with their research priorities, product portfolios, global rankings and competitive landscape
- Profiles of major companies within the industry, including: Novartis AG, Biogen, Bayer AG, Sanofi, and Teva Pharmaceutical Industries Ltd.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in Neuroprotective Agents Industry: ESG Perspective
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbvie Inc.
- Astrazeneca
- Bayer AG
- Biogen
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Gsk PLC.
- Lilly Usa LLC.
- Merck & Co. Inc.
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Ucb SA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 186 |
| Published | February 2026 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 43.9 Billion |
| Forecasted Market Value ( USD | $ 60.9 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
